• MEMBERS ACCESS
Members area access
ENHPATHY
  • TEAM
  • RESEARCH
  • TRAINING
    • RESEARCH SKILLS
    • TRANSFERABLE SKILLS
  • COMMUNICATION & DISSEMINATION
    • ENHANCER IN ART
    • ALL EYES ON ENHANCERS
  • NEWSROOM
    • EVENTS
  • ABOUT
    • CONSORTIUM
    • GOVERNANCE
    • PUBLICATIONS
    • RESOURCES
    • CONTACT
  • MEMBERS AREA
    • Cloud Storage
    • Videoconferences
    • Directory
  • Search
  • Menu Menu

Functional assay of regulatory elements could aid early detection of Congenital Heart Defects (CHD)

In the world of scientific investigations and innovative research, biomedical research offers a great many opportunities to contribute to improving both longevity and quality of life. An educational background in computer science and numerical computing intertwined with bioinformatics made me more conscious of the importance of the ENHPATHY initiative. ENHPATHY is not only an excellent research endeavour but also a significant step towards the humanitarian cause. During my stay in the UK, I was heavily involved in the COVID research on cancer patients with UK Coronavirus Cancer Monitoring Project (UKCCMP), which further motivated me to work towards health science and genetics-based research.

Congenital heart defects 

Congenital heart defects (CHD) are a varied group of structural and functional disorders that occur in the developing heart of neonates and children. CHD is the leading cause of infant morbidity and is prevalent in about 1-3% of all live newborns. Routine clinical diagnosis of CHD is often performed prenatally to examine the heart structure for defects in the walls, valves, and vessels. Surgical intervention and therapeutic management techniques for CHD have improved significantly over the last few decades and an early diagnosis and subsequent treatment have the potential to drastically improve perinatal outcomes. However, studies have found that a number of these CHD diagnoses are missed in the birthing clinic and thus infants are later diagnosed upon hospital admission for critical symptoms such as cardiac shock.

The advent of next-generation sequencing made prenatal genetic diagnosis possible. However, the underlying genetic architecture suggested that the causal CHD variants were found to be those identified on a family-by-family basis rather than identified statistically at a population level with GWAS (Genome-Wide Association Study). In conclusion, the theory of CHD aetiology became that many common variants, as detected by GWAS, add to the risk of CHD, but these exist alongside rare variants which carry a much higher contribution. Therefore, an unbiased whole-exome sequencing (WES) approach started to be utilized to identify rare causal sequence variants in familial or sporadic CHD cases. Unfortunately, due to poor diagnostic success rates of both CHD gene panels and WES, along with the limited genome-wide coverage of both methods, the focus is now turning to whole-genome sequencing (WGS) to investigate whether non-coding sequence variants can lead to an improved diagnostic yield for CHD.

Introducing SuRE and its potential role in new CHD variants identification

However, identification of variants is just the first step, major challenges lie within identifying causal variants amongst them. Due to the intricate spatial-temporal regulation of transcription-factor binding to non-coding cis-regulatory elements, the functional effect of these variants is not predictable just from the sequence. Functional assays are commonly employed alongside WGS to determine whether a variant has a functionally significant effect on gene expression. Survey of Regulatory Elements (SuRE) is a massively parallel reporter assay platform that can identify and assay novel promoters/enhancers at high throughput. Additionally, SuRE can assay CRE activity in any transfectable cell line and previous applications have found differing cell types to have unique regulatory profiles. We hypothesize that using SuRE technology, we would be able to detect some of these causal variants while establishing a database with millions of non-coding sequence variants – all functionally annotated for their effect on enhancer and promoter activity in several disease-relevant cell types. This database of non-coding sequence variants and causal variants would not only be a major accomplishment of the project but also an important resource for strategies aiming to link genotypes to phenotypes like the GWAS and eQTL (Expression Quantitative Trait Loci) studies.

Posted by Vartika Bisht
29 March 2021/by Vartika Bisht
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share by Mail
https://www.enhpathy.eu/wp-content/uploads/2021/03/AC16-cell-line.jpeg 680 1024 Vartika Bisht https://www.enhpathy.eu/wp-content/uploads/2019/11/logo-enhpathy-1.png Vartika Bisht2021-03-29 12:19:492021-03-29 14:08:49Functional assay of regulatory elements could aid early detection of Congenital Heart Defects (CHD)

LATEST NEWS

ENHPATHY highlighted in the Winter issue of EU Research

Pitch my Enhancer in art project in 90 seconds

Current challenges in understanding the role of enhancers in disease

Chronic inflammation decreases HSC fitness by activating the druggable Jak/Stat3 signaling pathway

QUESTION ABOUT ENHPATHY?

LET’S TALK!

Marie CurieThis project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 860002. The information contained in this website reflects only the authors’ view. REA and EC are not responsible for any use that may be made of this information.

Posted by Vartika Bisht
© Copyright - ENHPATHY
  • Twitter
  • Facebook
  • LinkedIn
  • Vimeo
  • SiteMap
  • Legal Notice
Enhancers
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyParamètres

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Legal Notice
Accept settingsHide notification only